Prof Roger Bayston responds to a long read on the difficulties facing drug and device development
I was interested to read about the life‑changing treatments being discarded because scientists run out of cash (The long read, 11 March). As Alexander Masters says, failure to move new medicines to commercial, and therefore clinical, use results in vast wastage of research resources and loss of valuable treatments because most never leave the lab. This also applies to implantable medical devices, which are in common use today.
New devices, particularly those that can significantly reduce complications such as infection, are potentially available, but, as with new drugs, often stay in the lab for want of commercial support to the next stages. Randomised clinical trials (RCTs) are often thought of as the “gold standard” next step, but many new drugs and devices fail at this stage. Those that pass the RCT, which as Masters says are not representative because of numerous restrictions on those taking part, can also fail when released into “real life” assessment on the general population. But these stages are essential to show safety and effectiveness.
About Author
More Stories
‘The longer I left it, the more it was going to freak me out’: how Will returned to the water after a close call with a shark
Scientists hail ‘avalanche of discoveries’ from Euclid space telescope
Psychologists in touch with Antarctic base after assault allegation, South Africa confirms